Halozyme, Baxter sales and marketing update

BAX exercised its option to expand its rights under the companies' 2004 deal to market HTI's Hylenex recombinant human hyaluronidase enzyme ( rHuPH20) (see BioCentury Aug. 23, 2004). BAX's rights now...